Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)[P1.04-31]
(2019) IASLC 2019 World Conference on Lung Cancer — Location: (Spain) Barcelona (7.September.2019)
Files
2019_Ferrara_J_Thorac_Oncol_P104-31.pdf
Open Access - Adobe PDF
- 314.02 KB
Details
- Authors
- Abstract
- BACKGROUND : CD28, CD57 and KLRG1 on circulating T-lymphocytes have been identified as markers of immunosenescence. The characterization of a senescent immune phenotype (SIP) in advanced NSCLC (aNSCLC) and its impact on anti-PD(L)-1 (IO) or platinum-based chemotherapy (PCT) treatments are unknown. [...]
- Affiliations
Citations
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Medhi, J. J., Boselli, L., Grivel, J., Desnoyer, A., Texier, M., Mezquita, L., Aboubakar Nana, F., Hendriks, L., Planchard, D., Caramella, C., Remon, J., Ngocamus, M., Nicotra, C., Proto, C., et al. (2019). Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)[P1.04-31]. Journal of Thoracic Oncology, 14(10), S452. https://doi.org/10.1016/j.jtho.2019.08.934 (Original work published 2019)